作者
Kevin Akeret, Raphael M Buzzi, Moritz Saxenhofer, Kathrin Bieri, Deborah Chiavi, Bart R Thomson, Manuela Grüttner-Durmaz, Nina Schwendinger, Rok Humar, Luca Regli, Tristan PC van Doormaal, Ulrike Held, Emanuela Keller, Michael Hugelshofer, Dominik J Schaer
发表日期
2022/7/18
期刊
BMC neurology
卷号
22
期号
1
页码范围
267
出版商
BioMed Central
简介
Introduction
Preclinical studies provided a strong rationale for a pathophysiological link between cell-free hemoglobin in the cerebrospinal fluid (CSF-Hb) and secondary brain injury after subarachnoid hemorrhage (SAH-SBI). In a single-center prospective observational clinical study, external ventricular drain (EVD) based CSF-Hb proved to be a promising biomarker to monitor for SAH-SBI. The primary objective of the HeMoVal study is to prospectively validate the association between EVD based CSF-Hb and SAH-SBI during the first 14 days post-SAH. Secondary objectives include the assessment of the discrimination ability of EVD based CSF-Hb for SAH-SBI and the definition of a clinically relevant range of EVD based CSF-Hb toxicity. In addition, lumbar drain (LD) based CSF-Hb will be assessed for its association with and discrimination ability for SAH-SBI.
Methods
HeMoVal is a prospective international …
学术搜索中的文章
K Akeret, RM Buzzi, M Saxenhofer, K Bieri, D Chiavi… - BMC neurology, 2022
